Literature DB >> 27394656

[Hypertensive disorders during pregnancy: Cardiovascular long-term outcomes].

B Alvarez-Alvarez1, N Martell-Claros2, M Abad-Cardiel3, J A García-Donaire3.   

Abstract

Pregnancy-induced hypertension (PIH) induces maternal and fetal damage, but it can also be the beginning of future metabolic and vascular disorders. The relative risk of chronic hypertension after PIH is between 2.3 and 11, and the likelihood of subsequent development of type 2 diabetes is multiplied by 1.8. Women with prior preeclampsia/eclampsia have a twofold risk of stroke and a higher frequency of arrhythmias and hospitalization due to heart failure. Furthermore, a tenfold greater risk for long-term chronic kidney disease is observed as well. The relative risk of cardiovascular death is 2.1 times higher compared to the group without pregnancy-induced hypertension problems, although the risk is between 4 and 7 times higher in preterm birth associated with gestational hypertension or pre-existing hypertension The postpartum period is a great opportunity to intervene on lifestyle, obesity, make an early diagnosis of chronic hypertension and DM and provide the necessary treatments to prevent cardiovascular complications in women.
Copyright © 2016 SEH-LELHA. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cardiopatía y embarazo; Cardiovascular complications in women; Chronic kidney disease and pregnancy; Complicaciones cardiovasculares en la mujer; Heart disease and pregnancy; Hipertensión en el embarazo; Hypertension in pregnancy; Ictus y embarazo; Insuficiencia renal y embarazo; Preeclampsia; Stroke and pregnancy

Mesh:

Year:  2016        PMID: 27394656     DOI: 10.1016/j.hipert.2016.06.002

Source DB:  PubMed          Journal:  Hipertens Riesgo Vasc        ISSN: 1889-1837


  9 in total

Review 1.  Residual vascular dysfunction in women with a history of preeclampsia.

Authors:  Anna E Stanhewicz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-08-22       Impact factor: 3.619

2.  Local angiotensin-(1-7) administration improves microvascular endothelial function in women who have had preeclampsia.

Authors:  Anna E Stanhewicz; Lacy M Alexander
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-10-02       Impact factor: 3.619

3.  Alterations in endothelin type B receptor contribute to microvascular dysfunction in women who have had preeclampsia.

Authors:  Anna E Stanhewicz; Sandeep Jandu; Lakshmi Santhanam; Lacy M Alexander
Journal:  Clin Sci (Lond)       Date:  2017-11-23       Impact factor: 6.124

4.  Increased Angiotensin II Sensitivity Contributes to Microvascular Dysfunction in Women Who Have Had Preeclampsia.

Authors:  Anna E Stanhewicz; Sandeep Jandu; Lakshmi Santhanam; Lacy M Alexander
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

5.  Acute systemic inhibition of inflammation augments endothelium-dependent dilation in women with a history of preeclamptic pregnancy.

Authors:  Anna E Stanhewicz; Gabrielle A Dillon; Corinna Serviente; Lacy M Alexander
Journal:  Pregnancy Hypertens       Date:  2021-12-28       Impact factor: 2.899

6.  Women with a history of preeclampsia have preserved sensory nerve-mediated dilatation in the cutaneous microvasculature.

Authors:  Michael Pyevich; Lacy M Alexander; Anna E Stanhewicz
Journal:  Exp Physiol       Date:  2022-01-09       Impact factor: 2.969

Review 7.  Maternal microvascular dysfunction during preeclamptic pregnancy.

Authors:  Anna E Stanhewicz; Virginia R Nuckols; Gary L Pierce
Journal:  Clin Sci (Lond)       Date:  2021-05-14       Impact factor: 6.876

8.  Postpartum Sequelae of the Hypertensive Diseases of Pregnancy: A Pilot Study.

Authors:  Ochuwa Adiketu Babah; Olalekan Olaleye; Bosede B Afolabi
Journal:  Niger Med J       Date:  2018 Jan-Feb

9.  The Risk and Clinical Treatment of Hypertensive Diseases in Pregnant Women.

Authors:  Jie Xu; Xin Yu; Zhimin Wang
Journal:  Biomed Res Int       Date:  2022-09-05       Impact factor: 3.246

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.